IRVINE, Calif. — Allergan’s net earnings for the quarter ended March 31 rose to $230.3 million, up from $158.8 million in the same quarter last year, according to a news release.
Product net sales totaled $1.365 billion in the first quarter, up 9% from the previous year’s first quarter, the release said.
"In the first quarter, Allergan delivered strong operating results as we continued to benefit from product approvals and operating in many growing markets," David E.I. Pyott, Allergan's chairman of the board, president and chief executive officer, said in the release. "In addition, as discussed at our Research & Development Technology Review in March, we have a robust R&D pipeline that should fuel additional growth over the long term."
In January Senju Pharmaceutical gained approval to market Alphagan P (brimonidine tartrate ophthalmic solution 0.1%) in Japan for reduction of IOP in patients with ocular hypertension and/or glaucoma, the release said.
Allergan is expecting product net sales between $1.45 billion and $1.5 billion for the second quarter, according to the release.